Primer agreement provides ability to purchase up to 20 million primers per month alongside additional inspection equipment and strengthened raw material sourcing
HAGERSTOWN, MD / ACCESS Newswire / November 3, 2026 / First Breach Inc. (NASDAQ:FBDT) (“First Breach” or the “Company”), an American-made defense technologies company focused on vertically integrated ammunition production and next-generation unmanned aerial systems, today announced an agreement with a strategic supplier that gives the Company the ability to purchase up to 20 million primers per month. First Breach has also received two additional pieces of ammunition inspection equipment and entered into a separate agreement with a key raw material supplier to support reliable material availability as production scales.
These developments build on the Company’s previously announced investment in loading and inspection equipment at its Hagerstown, Maryland facility and support its plans to scale ammunition production toward capacity of up to 20 million rounds per month as it expands on its current seven-day production schedule and transitions toward 24-hour operations.
The primer agreement supplements First Breach’s existing vendor relationships, providing an additional source for one of the two finished ammunition components the Company purchases externally. Primers and propellant powder are the only finished ammunition components First Breach sources from outside suppliers; the Company manufactures its other components in-house, including brass cups, casings, projectiles, lead cores and lead wire.
The two additional inspection units supplement equipment acquired earlier this year and are intended to expand inspection throughput at the Company’s ISO 9001:2015-certified Hagerstown facility. Together with rigorous quality controls throughout production, the added inspection capability is designed to support higher ammunition volumes while maintaining precision and consistency.
The raw material agreement strengthens access to the materials First Breach smelts and processes in-house, helping align sourcing with its planned production ramp. More favorable supply terms support the reliability and availability of these materials, providing a strategic advantage as manufacturing scales.
“Equipment capacity must be matched by dependable material supply and consistent quality control,” said Jeffrey Low, CEO of First Breach. “These steps bring our sourcing and inspection capabilities into closer alignment with our production plans. We are building on our investments in Hagerstown to support higher output and respond reliably to growing customer demand.”
About First Breach
First Breach Inc. is an ISO 9001:2015 certified, American-made defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing next-generation unmanned aerial systems for commercial, law enforcement, and military markets. The Company manufactures its products in-house at its Hagerstown, Maryland facility, where it produces brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition with rigorous quality control standards. First Breach is also advancing its drone strategy through the development of U.S.-made unmanned systems, leveraging advanced engineering, robotics, ISR and sensor technologies, and precision manufacturing capabilities to address evolving defense, homeland security, law enforcement, and commercial requirements across domestic and international markets.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and include statements regarding the Company’s expectations, beliefs, plans, objectives, strategies, future events, future performance, business prospects, growth initiatives, acquisitions, market opportunities, capital resources, operational objectives, and other statements that are predictive in nature. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations, assumptions, and beliefs regarding future developments and their potential effect on the Company. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in economic, business, market, competitive, regulatory, technological, legal, and geopolitical conditions; the Company’s ability to execute its business strategy; access to capital and financing; customer demand; industry developments; and other risks and uncertainties described from time to time in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, the Company undertakes no obligation to update, revise, or publicly disclose any revisions to any forward-looking statements to reflect events, circumstances, or changes in expectations occurring after the date of this press release.
First in a planned programme of acquisitions to expand Davion’s revenues, earnings and healthcare operations
DUBLIN, Oct. 29, 2026 (GLOBE NEWSWIRE) — Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Group”), a developer of non-invasive health monitoring technologies, announces that it has entered into an agreement dated 27 October 2026 to acquire Healthcare Stat Homecare Inc. (“HSH”), a Pennsylvania-incorporated provider of home healthcare services based in Philadelphia.
The total consideration is $13.5 million, comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. Completion is expected on or before 31 December 2026, subject to the terms of the acquisition agreement.
HSH is an established, revenue-generating and profitable healthcare services business. For the year ended 31 December 2025, HSH reported gross receipts of approximately $11.6 million and ordinary business income of approximately $1.9 million (unaudited). The acquisition is expected to provide Davion with an established operating business and an additional source of revenue and earnings following completion.
The proposed acquisition represents the first in a planned programme of acquisitions of established, revenue-generating and profitable healthcare businesses over the coming year. This strategy is intended to complement Davion’s existing portfolio of proprietary healthcare technologies, broaden its commercial operations and build a more diversified healthcare group.
HSH provides skilled nursing, home health aide and rehabilitation services to patients in Philadelphia and surrounding areas. Its clinical programmes include wound care, lymphedema management, dementia and diabetes care, telehealth and rehabilitation. Its workforce includes registered nurses, licensed practical nurses, home health aides, physical and occupational therapists and social workers.
HSH provides care to patients of all ages, from children to the elderly, helping individuals remain in their own homes rather than requiring residential or institutional care. According to its website, HSH holds JCAHO accreditation and Medicare and Medicaid certifications, is fully insured and bonded, and accepts major insurance plans.
The acquisition would also extend Davion’s activities beyond the development and commercialisation of healthcare products into the delivery of care in patients’ homes. It could provide opportunities to evaluate the use of Davion’s non-invasive monitoring technologies in home healthcare, including wound monitoring and preventative care. Any integration or deployment plans will be developed following completion.
Glenn Williams, Chief Executive Officer of Davion, commented:
“HSH is an established and profitable business that will bring meaningful revenues and earnings to Davion, while giving us a direct presence in home healthcare and opportunities to introduce our monitoring and diagnostic technologies closer to patients. Importantly, this is the first in a planned programme of acquisitions of revenue-generating, profitable healthcare businesses over the coming year, as we look to build a broader and more diversified Group combining our proprietary technologies with established operating businesses. We look forward to working with HSH’s management to support its existing operations and explore opportunities to integrate our technologies into the delivery of care at home.”
Manilal Mathai, Co-owner and Chief Executive Officer of HSH, added:
“We share Davion’s commitment to improving care for patients outside hospital settings. Joining forces would give us an opportunity to combine HSH’s home healthcare experience with Davion’s technology-led approach, while continuing to focus on the quality and continuity of care we provide to patients and families.”
Mark Komonoski Partner Integrous Communications Toll Free: 877-255-8483 Mobile: 403-470-8384
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.
The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.
The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
Vancouver, British Columbia–(Newsfile Corp. – October 29, 2026) – West Point Gold Corp. (TSXV: WPG) (OTCQX: WPGCF) (FSE: LRA0) (“West Point Gold” or the “Company”) is pleased to announce that it has received approximately C$4.1 million from the exercise of outstanding warrants, further strengthening its treasury ahead of its planned 30,000-metre drill program at the flagship Gold Chain Project in Arizona. The additional capital positions the Company to execute its planned exploration activities through May 2027 while maintaining financial flexibility.
“The significant exercise of outstanding warrants reflects continued investor confidence in West Point Gold and the direction we’re taking at Gold Chain. This support has further strengthened our balance sheet, providing the financial flexibility to execute our planned 30,000-metre drill program through May 2027 while maintaining a strong treasury. We plan to build on that confidence through disciplined execution, expanding the known mineralized footprint, testing new targets, and demonstrating the broader potential of Gold Chain. We believe the work ahead represents an important opportunity to create meaningful long-term value for our shareholders,” stated Derek Macpherson, President & CEO.
Gold Chain Exploration Program and Warrant Exercise Update The planned 30,000-metre drill program at Gold Chain should expand the known mineralized footprint and test additional exploration targets. The Company expects to provide updates as drilling progresses and results become available.
Since June 30, 2026, the Company has received approximately C$4.1 million from warrant exercises. The remaining outstanding warrants and their expiry dates are summarized in Table 1.
Table 1: Outstanding Warrants
EXPIRATION
EXERCISE PRICE
WARRANTS
VALUE
15-NOV-2026
$0.40
1,720,179
$688,072
10-JUN-2027
$0.45
53,334
$24,000
10-JUN-2027
$0.55
6,599,400
$3,629,670
19-FEB-2028
$1.10
1,045,455
1,150,000
TOTAL
9,418,368
$5,491,742
About West Point Gold Corp. West Point Gold is an exploration and development company focused on unlocking value across four strategically located projects along the prolific Walker Lane Trend in Nevada and Arizona, USA, providing shareholders with exposure to multiple discovery opportunities across one of North America’s most productive gold regions. The Company’s near-term priority is advancing its flagship Gold Chain Project in Arizona.
For further information regarding this press release, please contact: Aaron Paterson, Corporate Communications Manager Phone: +1 (778) 358-6173 Email: info@westpointgold.com
FORWARD-LOOKING STATEMENTS: Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. Forward-looking statements include estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events including, among others, assumptions about future prices of gold, silver, and other metal prices, currency exchange rates and interest rates, ability to define economic mineralization, favourable operating conditions, political stability, obtaining government approvals and financing on time, obtaining renewals for existing licenses and permits and obtaining required licenses and permits, labour stability, stability in market conditions, availability of equipment, availability of drill rigs, and anticipated costs and expenditures. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to West Point Gold’s ability to complete any payments or expenditures required under the Company’s various option agreements for its projects; and other risks and uncertainties relating to the actual results of current exploration activities, the uncertainties related to resources estimates; the uncertainty of estimates and projections in relation to production, costs and expenses; risks relating to grade and continuity of mineral deposits; the uncertainties involved in interpreting drill results and other exploration data; the potential for delays in exploration or development activities; uncertainty related to the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results may vary from those expected; statements about expected results of operations, royalties, cash flows, financial position may not be consistent with the Company’s expectations due to accidents, equipment breakdowns, title and permitting matters, labour disputes or other unanticipated difficulties with or interruptions in operations, fluctuating metal prices, unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and regulatory restrictions, including environmental regulatory restrictions. The possibility that future exploration, development or mining results will not be consistent with adjacent properties and the Company’s expectations; operational risks and hazards inherent with the business of mining (including environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather); metal price fluctuations; environmental and regulatory requirements; availability of permits, failure to convert estimated mineral resources to reserves; the inability to complete a feasibility study which recommends a production decision; the preliminary nature of metallurgical test results; fluctuating gold prices; possibility of equipment breakdowns and delays, exploration cost overruns, availability of capital and financing, general economic, political risks, market or business conditions, regulatory changes, timeliness of government or regulatory approvals and other risks involved in the mineral exploration and development industry, and those risks set out in the filings on SEDAR+ made by the Company with securities regulators. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this corporate press release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, other than as required by applicable securities legislation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Federal investment and new procurement rules help push critical production back onto American lines
HAGERSTOWN, MD / ACCESS Newswire / October 29, 2026 / First Breach Inc. (NASDAQ:FBDT) (“First Breach” or the “Company”), an American-made defense technologies company focused on vertically integrated ammunition production and next-generation unmanned aerial systems, is advancing its Hagerstown manufacturing expansion as federal investment and procurement priorities reinforce demand for domestic defense production. The Company believes this shift reflects a lasting national security priority that extends beyond any single policy cycle.
The Pentagon’s roughly $1 billion Drone Dominance Program, announced in December 2025, aims to buy hundreds of thousands of American-made drones and is designed to give industry a steady, long-term demand signal. The program’s second phase, which takes effect this year, restricts motors and battery systems from covered countries.
“For 20 years, manufacturing decisions defaulted to building overseas because it was cheaper,” said Jeffrey Low, CEO of First Breach. “Basing decisions on cost alone is now over. One area where this country has decided it will no longer depend on foreign factories is the production of ammunition and drones for its own military and its own agencies’ needs. That is what reshoring looks like today, with U.S. manufacturers directly benefitting from billions of dollars in new contracts and investments in facilities and workers to meet increased demand.”
“This is what a serious reshoring effort should look like: policy and manufacturing capacity arriving together rather than years apart,” said Jordan Low, President and Chief Operating Officer of First Breach. “Anyone can say they support American manufacturing, but it’s just talk unless there is investment to back those words up, we are putting money where our mouth is by moving from a single product line to a vertically integrated ammunition and drone operation, built entirely on U.S. soil, on a timeline that gets ahead of the deadlines the federal government has set for itself.
First Breach is targeting scaled drone production at its Hagerstown campus by Q2 2027, ahead of the exemption deadline. The Company currently has approximately 80,000 square feet dedicated to ammunition manufacturing, with more than 200,000 additional contiguous square feet under development to expand ammunition production and establish drone manufacturing operations.
As part of this expansion, First Breach has conducted extensive testing of its American-made unmanned aerial systems, with two proprietary drone platforms now in active flight testing. Among its recent successes, the Company’s Close Quarters Strike platform has completed untethered flight, executed a fully autonomous mission from takeoff through landing along a predetermined satellite navigation route, and reached 100 mph in testing without a payload. Its larger Long Range Strike platform has also completed its initial test flight. The two platforms share components and manufacturing resources designed to support efficient, scalable production as development and testing continue. The company expects to complete initial drone prototypes by Q4 2026 with a target of scaled production in Q2 2027.
About First Breach
First Breach Inc. is an ISO 9001:2015 certified, American-made defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing next-generation unmanned aerial systems for commercial, law enforcement, and military markets. The Company manufactures its products in-house at its Hagerstown, Maryland facility, where it produces brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition with rigorous quality control standards. First Breach is also advancing its drone strategy through the development of U.S.-made unmanned systems, leveraging advanced engineering, robotics, ISR and sensor technologies, and precision manufacturing capabilities to address evolving defense, homeland security, law enforcement, and commercial requirements across domestic and international markets.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and include statements regarding the Company’s expectations, beliefs, plans, objectives, strategies, future events, future performance, business prospects, growth initiatives, acquisitions, market opportunities, capital resources, operational objectives, and other statements that are predictive in nature. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations, assumptions, and beliefs regarding future developments and their potential effect on the Company. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in economic, business, market, competitive, regulatory, technological, legal, and geopolitical conditions; the Company’s ability to execute its business strategy; access to capital and financing; customer demand; industry developments; and other risks and uncertainties described from time to time in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, the Company undertakes no obligation to update, revise, or publicly disclose any revisions to any forward-looking statements to reflect events, circumstances, or changes in expectations occurring after the date of this press release.
Toronto, Ontario–(Newsfile Corp. – October 28, 2026) – Coyote Copper Mines Inc. (TSXV: CCMM) (“Coyote Copper” or the “Company”) is pleased to provide an exploration update from its Copper Springs Project in Arizona’s Copper Triangle (Figure 1). Since the February and March geophysical programs, the Company has expanded its land position and carried out additional geophysical surveys, surface mapping and sampling to refine drill targets. Proceeds from the accelerated warrant exercise provided funding for the expanded exploration and staking program. Drilling is scheduled to begin around November 16, 2026.
Dan Weir, CEO of Coyote Copper Mines Inc., commented;
“Coyote Copper has signed Confidentiality Agreements (“CA’s”) with 6 major copper mining companies some of which have visited the project multiple times. Other company visits are being planned.”
“After successful geophysics programs in February and March of 2026, the company increased the original USD$200,000 geophysics budget to USD$1,500,000, increased our land position, and added expanded soil geochem and rock sampling programs. This effort was endorsed by the six major copper mining companies with which we have signed CA’s. The project continues to return great results and demonstrates the potential for multiple porphyry copper deposits. The expanded exploration program is ongoing, with efforts focused on prioritizing Phase One drill targets from our 37 permitted drill sites. With such a huge project and so many viable targets being revealed, we expect to be making a huge impact in the area, and for our investors.”
Highlights
● 214 additional claims have been staked, bringing Copper Springs to 1,100 claims covering approximately 22,086 acres (89.4 km²) (Figure 2).
● Rock chip results (Figure 3, Table 2):
○ West Gibson: 19.25% Cu over 0.60 m.
○ Around Gibson: 13.79% Cu over 0.30 m.
○ Maher: 0.54% Cu and 4,841.8 ppm molybdenum (Mo) over 0.50 m.
Assays are pending for 1,056 soil samples, 117 rock samples and 46 channel samples (Table 1). Regional soil sampling is complete across the expanded land position. A further 679 soil samples are planned for infill over the Santa Ana chargeability anomaly and surrounding targets.
● Drone surveying began on October 19 to extend magnetic coverage beyond the February survey area and collect radiometric data across the Project.
● Strong chargeability response near Santa Ana is evident in preliminary induced polarization (IP) results. TMC Geophysics and Zonge Geophysics continue IP and electromagnetic surveys across the Project (Figure 6, Table 3).
● Major Drilling is scheduled to begin drilling around November 16, 2026. Permits cover road construction and 37 drill locations (Figure 9). Phase 1 will test shallow oxide and deeper sulfide targets.
Regional Setting and Exploration Focus
Copper Springs lies near Globe and Miami in Arizona’s Copper Triangle, within the porphyry copper belt that hosts Pinto Valley, Miami and Resolution (Figure 1).
Figure 1. Location of Copper Springs among copper deposits and operations in Arizona’s Copper Triangle.
The Company recently staked 214 additional claims based on geophysical and soil sampling results. The expanded land position now includes 1,100 claims, up from 886, and covers approximately 22,086 acres (89.4 km²). Additional mapping and soil sampling are planned or in progress across the expanded project area.
Figure 2. Existing and newly staked claims at Copper Springs.
Copper assay results are available for 2,729 of the 3,948 rock, channel and soil samples collected during the program (Table 1). Rock and channel sampling characterize exposed mineralization (Figure 3), while soil surveys outline geochemical patterns across a wider area for comparison with mapped geology and geophysical responses.
Table 1. Surface Sampling
Sample type
Collected
Cu assays
Rock
454
337
Channel
399
353
Soil
3,095
2,039
Channel sampling totals 396.39 m across 399 samples. Assays are pending for 1,056 of the collected soil samples.
Grab, dump and selective chip samples may not represent the average grade of the mineralization.
Figure 3. Rock and channel copper assays (%) over spectral IP phase at 800 m elevation.
Rock and channel sampling tests copper-bearing quartz veins, faults and exposed mineralization at West Gibson, area around the Gibson Mine, Santa Ana and MF. Table 2 presents samples returning at least 1% Cu, together with selected molybdenum and channel results.
These results exclude samples reported in the Company’s October 1, 2025 and April 30, 2026 news releases and historical 2016 Teck samples.
Table 2. Significant Surface Sampling Results
Sample
Target
Type
Width (m)
Easting
Northing
Cu (%)
Mo (ppm)
Ag (g/t)
Certificate
2027129
West Gibson
Rock chip
0.60
503463
3688553
19.25
18.50
17.85
SP0158872
2027134
West Gibson
Rock chip
0.80
503433
3688611
10.63
37.40
15.30
CYTE26-001
1844755
West Gibson
Rock chip
0.60
503483
3688696
8.06
21.00
10.07
SP0156942
2027150
West Gibson
Selective grab (dump)
503595
3688978
6.19
36.50
2.90
CYTE26-001
2027151
West Gibson
Rock chip
503563
3689006
4.46
6.70
0.90
CYTE26-001
2027127
West Gibson
Rock chip
0.50
503401
3688576
4.38
14.40
5.34
SP0158872
2027126
West Gibson
Dump grab
503365
3688475
4.32
4.90
4.22
SP0158872
2027124
West Gibson
Rock chip
1.00
503285
3688376
3.84
9.40
1.62
SP0158872
2027145
West Gibson
Selective grab (dump)
503368
3688516
3.79
1.70
4.40
CYTE26-001
2027152
West Gibson
Rock chip
503572
3688923
3.08
6.90
3.30
CYTE26-001
1844757
West Gibson
Rock chip
0.70
503515
3688737
2.84
8.00
1.85
SP0156942
1844756
West Gibson
Rock chip
0.45
503483
3688693
1.90
4.30
9.84
SP0156942
2027142
West Gibson
Rock chip
503437
3688544
1.63
0.90
0.70
CYTE26-001
2010815
West Gibson
Rock chip
1.00
503365
3688504
1.44
2.50
2.50
CYTE26-006
1844758
West Gibson
Rock chip
0.25
503519
3688741
1.19
8.10
1.25
SP0156942
2027133
West Gibson
Rock chip
1.00
503422
3688599
1.18
0.70
7.90
CYTE26-001
2027125
West Gibson
Rock chip
1.50
503282
3688374
1.09
2.00
1.00
SP0158872
1844753
Around Gibson
Rock chip
0.30
504161
3688477
13.79
17.60
28.85
SP0156942
1844752
Around Gibson
Rock chip
0.20
504153
3688474
6.30
10.20
8.87
SP0156942
1844750
Around Gibson
Rock chip
0.60
504155
3688472
5.93
5.80
1.80
SP0156942
2027171
Around Gibson
Rock chip
1.00
504120
3688459
4.83
0.90
0.40
CYTE26-001
2027165
Around Gibson
Selective chip
0.20
503719
3688097
4.07
7.60
10.70
CYTE26-001
1844748
Around Gibson
Selective grab
504698
3687492
3.75
168.40
2.38
SP0156942
1844749
Around Gibson
Rock chip
0.60
504155
3688473
3.66
8.60
5.46
SP0156942
2027164
Around Gibson
Rock chip
1.00
503683
3688323
3.07
9.20
2.10
CYTE26-001
2027172
Around Gibson
Selective chip
1.00
504527
3688429
3.05
4.20
1.10
CYTE26-001
2027153
Around Gibson
Rock chip
1.00
504429
3688531
2.34
2.10
6.00
CYTE26-001
2027154
Around Gibson
Rock chip
0.50
504459
3688544
2.28
0.50
2.00
CYTE26-001
2027155
Around Gibson
Rock chip
0.80
504459
3688544
1.90
0.80
1.20
CYTE26-001
2027156
Around Gibson
Selective chip
0.50
504459
3688544
1.09
0.20
0.30
CYTE26-001
1844751
Around Gibson
Rock chip
1.20
504154
3688473
1.06
2.40
0.60
SP0156942
2010533
West Lobe
Dump grab
507975
3688755
3.23
211.00
0.60
CYTE26-005
2010579
Santa Ana
Rock chip
1.00
509083
3689147
1.88
28.90
1.80
CYTE26-006
2010212
Rock chip
0.50
509433
3689521
1.42
8.40
3.66
SP0158872
2010225
BP 4
Rock chip
0.50
507232
3690652
1.12
9.40
6.50
SP0158872
2010546
Rock chip
508812
3689589
1.03
734.00
11.60
CYTE26-006
2010922
MF BX
Channel
1.00
509229
3689501
0.91
3.30
1.60
CYTE26-005
2010202
Maher
Rock chip
0.50
509105
3690051
0.54
4,841.80
1.44
SP0158872
2010544
Rock chip
508820
3689652
0.43
1,500.00
1.00
CYTE26-006
2010543
Rock chip
508825
3689691
0.19
2,000.00
0.60
CYTE26-006
2010594
Rock chip
508816
3689230
0.17
3,030.00
1.60
CYTE26-006
2010565
Santa Ana
Rock chip
1.50
508950
3689044
0.14
1,850.00
6.00
CYTE26-006
2010536
Rock chip
508731
3689866
0.013
1,480.00
0.10
CYTE26-006
2010556
Black Rock
Rock chip
1.50
505877
3682220
2.78
4.10
19.60
CYTE26-006
2026316
Poly BX
Tailings grab
506670
3684380
1.60
92.00
64.20
SP0155090
2010224
Red Rock QSP
Rock chip
0.50
505008
3683253
1.41
37.80
79.51
SP0158872
2026308
Red Rock QSP
Rock chip
504980
3683226
1.27
4.00
3.20
SP0155090
2026306
Red Rock QSP
Dump grab
504951
3683198
1.18
1.00
0.40
SP0155090
Coordinates are WGS84 UTM Zone 12N. Blank widths indicate that no sample width is reported. Widths are sampled lengths and are not true widths.
Soil Geochemistry
Soil copper anomalies help guide follow-up exploration in the area close to Gibson, West Gibson and Santa Ana exploration areas highlighted in Figure 4. Regional soil sampling has been completed across the remaining areas within the new project boundary at 100 m and 200 m spacing, with 1,056 samples awaiting assays.
Figure 4 shows the previously reported soil copper anomalies in relation to the mapped exploration targets. A further 679 soil samples are planned over the Santa Ana chargeability anomaly and surrounding targets.
Geophysical surveying continues across the Project, including 2D IP work tying Gibson to the Santa Ana area across the IP “Donut” (Figure 5). Preliminary 2D IP results show a strong chargeability response near Santa Ana (Figures 6 to 8).
Figure 5. Planned IP lines and CSEM stations over spectral IP phase at 600 m elevation.
Field mapping has focused on ground-truthing the geophysical signatures. The strongest chargeability response lies west of the main surface copper occurrences (Figure 6), and this south-western high reaches surface at two locations that coincide with copper oxides. The sulfide mineralization exposed at MF Creek and Santa Ana correlates with an intermediate chargeability response. Assays are pending for many of the samples collected over the chargeability high. Mapping and assay results will guide drillhole placement to test whether the exposed mineralization connects with the chargeability response at depth.
Figure 6. Surface copper assays in percent over modeled chargeability at 1,300 m above sea level.
Structural mapping has recorded 3,614 measurements to date: 3,428 veins, 145 faults and 41 other structures. The mapped veins and faults extend across the chargeability response (Figure 7), and they are being used to define the structural controls on mineralization and to target drilling for both shallow and deep targets.
Figure 7. Vein and fault measurements over modeled chargeability at 1,400 m elevation.
Intersecting chargeability sections L1N and L6E show the modeled response beneath the surface geology (Figure 8). The response is strongest on L1N beneath the Santa Ana area and weaker on the intersecting L6E section. The three-dimensional view also shows that much of the copper-sulfide mineralization is associated with intermediate chargeability outside the large south-western high, and this subsurface information is being used to plan drillhole intercepts with geophysical features.
Figure 8. Three-dimensional view of modeled chargeability sections L1N and L6E with surface geology and copper assays.
Permit approvals have been received for 37 Phase 1 drill locations, each capable of accommodating multiple drillholes. Road construction is advancing on schedule to support the November start of drilling. Figure 9 shows the planned access network and construction progress toward the initial drill sites. Major Drilling is scheduled to begin drilling around November 16, 2026.
Figure 9. Phase 1 access routes and permitted drill sites at Copper Springs.
The November 23, 2025 technical report contains no current mineral resource or mineral reserve estimate.
Sampling, Analysis And Quality Control
MineOro collected channel, rock chip and selective grab samples. Channels were cut with a diamond saw to approximately 3 inches depth, and continuous rock chips were collected across marked intervals. Selective grabs were collected from outcrop and mine dumps. Sample types, locations, widths and analytical results are provided in Table 2.
Samples were uniquely numbered, bagged and sealed, with photographed sites and handheld GPS locations recorded in WGS84 UTM Zone 12N. Samples were securely stored before delivery or courier shipment to the analytical laboratories.
Soils were collected from B-C horizons at depths of 6 to 12 inches and sieved to 60 mesh in the field.
Verification included comparing assay data with field records and laboratory reports and reviewing standards, blanks and laboratory repeats. Rock laboratory repeats assess analytical precision. No field or coarse-reject duplicates were available in the reviewed rock dataset to assess sampling and preparation variability. For mapping, results below detection were assigned numerical values, primarily half the detection limit. Results above range without a final overlimit assay were capped at the reporting limit.
Skyline Assayers & Laboratories, Tucson, Arizona, prepared and analyzed rock, channel and soil samples. Skyline holds ISO/IEC 17025 accreditation for the relevant preparation and analytical methods.
Skyline determined total copper by multi-acid digestion with an AAS finish (CuT) and multielement concentrations by near-total multi-acid digestion with ICP-OES/ICP-MS (TE-5). Overrange copper was determined by long iodide titration and overrange molybdenum by single-element assay.
American Assay Laboratories (AAL), Sparks, Nevada, holds ISO/IEC 17025 accreditation. Rock preparation comprised crushing to 70% passing 2 mm, splitting 300 g and pulverizing to 85% passing 75 µm. Analysis used a 0.5 g four-acid plus boric acid digestion with ICP-OES or ICP-OES/ICP-MS (IO-4AB51 or IM-4AB52). Copper above 10,000 ppm was determined by ore-grade ICP-OES (IO-4ABOR).
ALS prepared 437 soil samples in Tucson, Arizona, by screening to minus 180 µm and analyzed them in North Vancouver, British Columbia, using a 0.5 g aqua regia digestion with ICP-MS/ICP-AES (ME-MS41L).
Skyline, AAL and ALS are independent commercial laboratories. MineOro conducts the sampling program for the Company.
MineOro’s field quality-control program includes certified reference materials and blanks at approximately 5% of the rock and channel sample stream, and certified reference materials and field duplicates at approximately 2% of the soil sample stream. Skyline and AAL also analyzed laboratory reference materials, blanks and duplicates with each batch. Some certified reference materials in the AAL soil batches returned low copper recoveries. The soil results were accepted for reconnaissance interpretation.
Qualified Persons
Michael N. Feinstein, PhD, CPG, of MineOro, is the Company’s project Qualified Person and is independent of the Company under NI 43-101. He prepared, reviewed and approved the scientific and technical disclosure in this release and has verified the supporting data. Bay Woods, CPG, prepared or supervised implementation of the maps and figures and monitored QA/QC. Both are Qualified Persons under National Instrument 43-101, Standards of Disclosure for Mineral Projects.
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Information
This news release contains statements that constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding ongoing and proposed exploration activities, completion and interpretation of geophysical surveys, construction of access roads and drill pads, commencement and timing of drilling, and the objectives and potential results of exploration programs.
Forward-looking information is often, but not always, identified by words such as “plans,” “expects,” “is expected,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates,” “believes,” “may,” “could,” “would,” “might” or “will.” Forward-looking information is based on management’s current expectations, estimates, assumptions and beliefs and is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. Such risks include risks applicable to mineral exploration companies, including title, permitting, environmental, exploration, contractor availability, financing and commodity-price risks.
There can be no assurance that forward-looking information will prove to be accurate. Readers should not place undue reliance on forward-looking information. Forward-looking information contained herein is made as of the date of this news release and, except as required by applicable law, the Company disclaims any obligation to update or revise such information as a result of new information, future events or otherwise.
This transaction will be accretive to earnings per share for the current Ai² shareholders.
Based on projections provided by Messier 42, it is expected that the Services Agreement will generate approximately $125 million in cash for Ai² in 2027 based on the current sales pipeline
DALLAS, TX / ACCESS Newswire / October 27, 2026 / AIAI Holdings Corporation (NASDAQ:AIAI) (“Ai² ” or the “Company”), an AI-enabled diversified holding company utilizing Transformational AI to enhance portfolio performance, today announced that they are partnering with Messier 42 LLC (“M42”), under common control with Ai², to create a War Tech Consortium (the “Consortium”).
Under the terms of a services agreement (described below), the Consortium will pursue the acquisition of, and strategic partnerships with, defense technology companies to commercialize and distribute products and services in the US and internationally, subject to applicable regulations. Through the combined resources and expertise of Ai² and M42, the Consortium intends to enhance the capabilities, operational efficiency and market potential of its portfolio companies and contractual relationships by integrating Ai²’s proprietary Transformational Artificial Intelligence (“TAI”) across their products, services, and business operations.
The speed at which the portrait of war is changing is at a point that humans have not dealt with in our known history. The Consortium will focus on applying psychometric Ai, a key component of TAI, to the central platform brain which we expect will create an opportunity for the immediate insertion of new weaponry and cyber security bots. Mankind needs an ally from the individual to the sovereign state level. The same is increasingly the case in commercial realm where terrorist threats are more frequent than ever.
This announcement is an expansion of the transaction described in of the press release dated September 18, 2026, describing the capital contribution to be made by M42 to Ai² of a controlling interest in the M42 subsidiary that has a sales representative agreement to enhance and sell anti-drone technology (the “Existing Agreement”). The new collaborative arrangement with M42 will be undertaken pursuant to a services agreement entered into between Ai² and M42 on October 26, 2026 (the “Services Agreement”). Under the Services Agreement, Ai² will provide services to M42 necessary to develop and enhance the Consortium’s business relationships. Ai² and M42 will work together to assemble a portfolio of defense related entities the operations of which are expected be enhanced by the Consortium’s technology to collectively address contemporary and future military threats. In consideration for providing these services, the Company will receive a percentage of the net proceeds generated by the Consortium’s businesses, beginning with the right to receive 50% of the net proceeds generated by the Existing Agreement. The Existing Agreement is the first of what the companies believe will be several similar transactions acquired or developed by the Consortium.
While the transaction does not provide for a controlling interest in the M42 subsidiary as previously announced, it reflects a much broader strategic approach to defense technologies addressing both current and emerging security needs. It also recognizes growing commercial demand for advanced defense and protective technologies to safeguard high value fixed assets, including professional and collegiate sports stadiums, shopping malls and other commercial, municipal and state facilities.
This transaction will be accretive to earnings per share for the existing Ai² shareholders. Based on its projections, M42 anticipates that the Services Agreement will generate approximately $125 million in cash for Ai² in 2027 based on the current sales pipeline.
This transaction represents a deepening of the mutually beneficial relationship between M42 and Ai² and underscores their continuing conviction in Ai²’s long-term strategy, its differentiated position in TAI, and the ability of its Board and management team to execute at scale. The Rochon family which control M42 have been associated with Ai² since its inception, and the Services Agreement between the two entities further align their interests with Ai²’s long-term value creation objectives.
“The management team of Ai² and its Board of Directors have demonstrated already their remarkable capabilities as a team to execute on the company’s vision and strategy. Further, my family and I have a vested interest in their success and in working together to create value that will lead to a safer world,” said Chairman John Rochon.
“We are grateful for the continued confidence that the Rochon Family has in our team. This strategic transaction will fundamentally strengthen the Company by enhancing our cash position allowing us to build on our long-term strategy without dilution to shareholders” said Todd Furniss, Ai²’s Chief Executive Officer.
About AIAI Holdings Corporation
AIAI Holdings Corporation (Ai²) (NASDAQ:AIAI) is an AI-enabled diversified holding company that acquires and grows companies across multiple industries. We expect to drive revenue and earnings growth throughout our portfolio by applying exclusively licensed Transformational AI to enhance operational efficiency and financial performance.
Ai² is building a next-generation model for technology-enabled business operations, which is expected to create sustainable value for shareholders through the strategic integration of artificial intelligence across diverse industries. More information can be found at: www.aiaiholdings.com
This press release contains “forward-looking statements” or “forward-looking information” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and plans of the Company, including, without limitation, M42’s projections of revenues that it expects to be generated by the business relationships subject to the Services Agreement. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations, intentions, beliefs, plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Forward-looking statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “would,” “could,” “should”, “estimate,” “plan,” “predict,” “project,” “estimate”, or “continue,” or similar expressions, including the negative of these terms or other comparable terminology.
Forward-looking statements are based on the Company’s current expectations regarding its strategy, plans, intentions, performance, or future occurrences or results, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events, including the third-party revenue projections described herein, and are subject to a number of known and unknown risks, uncertainties, and other factors, many of which are outside of the Company’s control, that could cause actual results, performance, or achievements to materially differ from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to our lack of operating history, our ability to attract new investments, our failure to manage growth effectively, our acquisition activities may pose risks that could harm our business, and our licensed AI may not perform up to the expected standards, as well as general business and economic conditions, competitive pressures, regulatory changes, technological developments, and other factors identified in the Company’s most recent filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1, which are available for review at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results.
The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any intention to, and, except as may be required by law, undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter become aware. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Relations
Matthew Selinger, Senior Partner Integrous Communications Email: mselinger@integcom.us Phone: 415-572-8152
Visit and follow AIAI Holdings Corporation online:
Larger of the Company’s two Class 1 attritable platforms takes to the air, joining the Close Quarters Strike platform already in-flight testing.
Long Range Strike platform is designed for greater than 20 km range, ~ 1 kg payload, and fully non-Chinese sourcing of all key electronic and power components, with production scaling targeted for Q2 2027
HAGERSTOWN, MD / ACCESS Newswire / October 27, 2026 / First Breach Inc. (NASDAQ:FBDT) (“First Breach” or the “Company”), an American-made defense technologies company focused on vertically integrated ammunition production and next-generation unmanned aerial systems, today announced the successful initial test flight of its Long Range Strike (“LRS”) platform, the second of the two proprietary drone platforms under development with Hellbender, Inc. Both the LRS and the Company’s Close Quarters Strike (“CQS”) platform are now in active flight testing.
Close Quarters Strike and Long Range Strike platforms
“Having both platforms in flight testing is an important step in expanding our drone product portfolio,” said Jeffrey Low, Co-Founder and Chief Executive Officer of First Breach. “These two aircraft share components, share a supply chain, and share a production line. That was the plan from the first day of the Hellbender agreement, and today both of them are flying. For the long-range mission, this is the platform the Department of War has been describing, built the way they have asked for it to be built.”
The LRS is a compact, man-portable Class 1 unmanned aircraft system weighing under 9 kg (20 lb.), with propellers under 457 mm (18 in) and a wheelbase or folded wingspan under 350 mm. The platform is designed for a range in excess of 20 km, a current speed of approximately 120 km/h, and a payload of ~1 kg. Operators control the aircraft in first-person view, with computer vision search assistance layered over map-based waypoint navigation. Onboard hardware is intended to support identification friend or foe and terminal guidance, while modular radio connectivity and GNSS-denied navigation hardware are intended to support resilience in environments affected by electronic warfare. Designed from inception for high-volume robotic assembly, the LRS sourcing plan calls for 100 percent non-Chinese sourcing of its battery pack, motors, power electronics, flight control system, flight computer, and vision guidance system.
The milestone advances First Breach’s development of two distinct products built around common components, a shared supply chain, and a common production line. This approach is intended to support manufacturing efficiency and scalable assembly as the Company progresses toward commercialization. First Breach continues to target completion of its initial prototypes in the fourth quarter of 2026 and the start of scaled production in the second quarter of 2027.
About First Breach
First Breach Inc. is an ISO 9001:2015 certified, American-made defense technologies company focused on manufacturing match-grade ammunition components, finished ammunition, and developing next-generation unmanned aerial systems for commercial, law enforcement, and military markets. The Company manufactures its products in-house at its Hagerstown, Maryland facility, where it produces brass cups, casings, projectiles, lead cores, lead wire, and completed ammunition with rigorous quality control standards. First Breach is also advancing its drone strategy through the development of U.S.-made unmanned systems, leveraging advanced engineering, robotics, ISR and sensor technologies, and precision manufacturing capabilities to address evolving defense, homeland security, law enforcement, and commercial requirements across domestic and international markets.
Hellbender, Inc. is a Pittsburgh-based engineering and advanced manufacturing company specializing in physical AI, computer vision, drones, robotics, electronics design, and automated manufacturing. Operating from approximately 90,000 square feet of facilities, the company provides integrated product development capabilities spanning engineering, prototyping, printed circuit board assembly, advanced sensor integration, robotic manufacturing, and production testing. More than 25% of Hellbender’s workforce consists of military veterans, supporting its commitment to American manufacturing and technical innovation.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not historical facts and include statements regarding the Company’s expectations, beliefs, plans, objectives, strategies, future events, future performance, business prospects, growth initiatives, acquisitions, market opportunities, capital resources, operational objectives, and other statements that are predictive in nature. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar expressions, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management’s current expectations, assumptions, and beliefs regarding future developments and their potential effect on the Company. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements.
Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to, changes in economic, business, market, competitive, regulatory, technological, legal, and geopolitical conditions; the Company’s ability to execute its business strategy; access to capital and financing; customer demand; industry developments; and other risks and uncertainties described from time to time in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by applicable law, the Company undertakes no obligation to update, revise, or publicly disclose any revisions to any forward-looking statements to reflect events, circumstances, or changes in expectations occurring after the date of this press release.
Denver, Colorado–(Newsfile Corp. – October 26, 2026) – Elemental Royalty Corporation (NASDAQ: ELE) (TSX: ELE) (“Elemental” or the “Company“) is pleased to announce that it has completed the acquisition of four of the five royalty and streams from funds managed by Orion Mine Finance Management LP (collectively, “Orion“), as previously announced on September 21, 2026 (the “Acquisition“).
In conjunction with the Acquisition, Elemental has executed the amendment to the Company’s existing Revolving Credit Facility (the “Facility“), increasing the Facility from US$150 million to US$250 million, with a further US$50 million accordion feature (the “Accordion“).
Elemental Chief Executive Officer, Frederick Bell, commented: “We are pleased to complete the acquisition of key assets from Orion. In the month since the Acquisition was announced, i-80 have reported first results from their ongoing Mineral Point drill program that highlight the potential for the mineralized footprint to expand as well as updating their development plan to prioritize the project. In parallel, Silverco published a new PEA for the producing La Negra mine that doubles production compared to our previous valuation and highlights the significant growth potential embedded within the portfolio.
The expansion of our credit facility to US$250 million demonstrates the continued support of our lending partners and provides us with greater financial flexibility going forwards to pursue further accretive royalty and streaming investments.”
Orion Portfolio
The acquired assets comprise the Ruby Hill Complex and Granite Creek silver stream, the Kouroussa gold stream, the Homestake District royalty and the La Negra royalty. The acquisition of the Snowy River gold stream is expected to close separately as planned in Q1 2027, subject to satisfaction of the applicable regulatory approvals in New Zealand.
Since the acquisition was announced, there have been a number of material updates on the assets:
Ruby Hill Complex and Granite Creek – i-80 Gold Corp.
i-80 has updated its development plan to prioritize Mineral Point as its next major development project, a key driver of anticipated production growth for the company. An ongoing infill and step-out drilling campaign has already demonstrated encouraging results, including the potential to expand the mineralized footprint. A Pre-Feasibility Study is targeted for mid-2027
La Negra – Silverco Mining Ltd.
Silverco has published a Preliminary Economic Assessment for La Negra, outlining an average annual production of 4.1 Moz AgEq1 over an 8.2-year mine life, with steady-state throughput of 2,500 tonnes per day beginning in H2 2027. A 15,000-metre surface and underground drill program, the first large-scale exploration effort at La Negra in two decades, is underway
Elemental paid upfront consideration for the four assets of US$188 million in cash and issued 3,942,881 common shares to Orion. Following the issuance of the consideration shares, the total number of issued and outstanding shares is 76,471,207.
Full details of the transaction can be found in Elemental’s news release titled “Elemental Royalty announces US$290 million Acquisition of Royalty and Streaming Portfolio, Strategic Divestment of Generation Business and Management Succession” dated September 21, 2026.
Credit Facility
The Company has entered into an agreement with National Bank of Canada (“NBC“), Canadian Imperial Bank of Commerce (“CIBC“), and The Bank of Nova Scotia (“Scotia“) (together “the Lenders“) for a US$250 million Facility, with an option to increase to a total of US$300 million through an Accordion feature of US$50 million, subject to the satisfaction of certain conditions. This is an amendment to the existing US$150 million facility.
The Facility has a term of three years, extendable through mutual agreement between Elemental and the Lenders. Depending on the Company’s leverage ratio, the amounts drawn on the Facility are subject to interest at SOFR plus 2.25%-3.5% per annum. Other material terms of the amended Facility are substantially consistent with the terms of the Company’s existing credit facility.
The Facility has been entered into by Elemental as borrower, NBC as Administrative Agent, National Bank of Canada Capital Markets as Sole Bookrunner and Co-Lead Arranger, and CIBC as Co-Lead Arranger and Syndication Agent.
Advisors
McCarthy Tétrault LLP is acting as legal advisor to Elemental on the Acquisition. Troutman Pepper Locke LLP is acting as U.S. legal counsel to Elemental. Fasken Martineau DuMoulin LLP is acting as legal advisor to Elemental on the Facility
National Bank of Canada Capital Markets is acting as financial advisor to Orion. Torys LLP is acting as legal advisor to Orion.
Qualified Person
The scientific and technical information contained in this news release has been reviewed and approved by Michael Sheehan, a consultant to the Company and a “Qualified Person” as defined in NI 43-101.
Elemental is a mid-tier, gold-focused streaming and royalty company with a globally diversified portfolio of approximately 20 producing assets and more than 260 royalties, anchored by cornerstone assets and operated by world-class mining partners. The Company’s disciplined capital allocation and investment strategy combines immediate cash flow with significant embedded growth, providing a differentiated pathway to long-term value creation. Elemental benefits from a high-quality and diversified asset base, strong organic growth potential and sector-leading management expertise.
Elemental trades on Nasdaq and on the Toronto Stock Exchange under the ticker Symbol “ELE”.
This news release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable United States and Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology (including negative and grammatical variations thereof).
Forward-looking statements and information include, but are not limited to, statements regarding completion of the Acquisition and other transactions described in this news release, including any required approvals, and the timing thereof; future royalties and future consideration payments or issuances of shares, or other statements that are not statements of fact. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies.
References to nearby mines, deposits and projects are provided for geological and regional context only. Mineralization on nearby or adjacent properties is not necessarily indicative of mineralization on the properties in which Elemental holds, or has agreement to acquire, a royalty interest.
Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of Elemental to control or predict, that may cause Elemental’s actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: the ability of the relevant parties to complete the Acquisition and the other transactions described in this news release; the receipt of approvals necessary for, and the satisfaction of other closing conditions to, the Acquisition; the impact of general business and economic conditions, the absence of control over the mining operations from which Elemental will receive royalties, risks related to international operations, government relations and environmental regulation, the inherent risks involved in the exploration and development of mineral properties; the uncertainties involved in interpreting exploration data; the potential for delays in exploration or development activities; the geology, grade and continuity of mineral deposits; the possibility that future exploration, development or mining results will not be consistent with Elemental’s expectations; accidents, equipment breakdowns, title matters, labour disputes or other unanticipated difficulties or interruptions in operations; fluctuating metal prices; unanticipated costs and expenses; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of production and cost estimates and the potential for unexpected costs and expenses, commodity price fluctuations; currency fluctuations; regulatory restrictions, including environmental regulatory restrictions; liability, competition, loss of key employees and other related risks and uncertainties. For a discussion of important factors which could cause actual results to differ from forward-looking statements, refer to the annual information form of Elemental for the year ended December 31, 2025. Elemental undertakes no obligation to update forward-looking statements and information except as required by applicable law. Such forward-looking statements and information represent management’s best judgment based on information currently available. No forward-looking statement or information can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.
Neither The Nasdaq Stock Market LLC nor the Toronto Stock Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange), accepts responsibility for the adequacy or accuracy of this news release.
1 Silver equivalent (“AgEq”) is calculated by dividing the total value of payable metal by the silver price, using the PEA price assumptions of $50.00/oz silver, $4.50/lb copper, $0.88/lb lead and $1.30/lb zinc. AgEq Produced applies the same conversion to metal recovered to concentrate. Payability, treatment and refining charges, transportation and penalties are reflected in the payable figures. Silverco Mining Ltd. news release 09/21/2026.
Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio
DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) — Davion Healthcare Plc (Nasdaq: DAVI) (“Davion” or the “Company”), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed the acquisition of the intellectual property relating to two medical technologies: WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform.
The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5 million in cash and 1,730,770 new ordinary shares in Davion, to be issued at an agreed fixed contractual value of US$13.00 per share (approximately US$22.5 million). The number of shares is fixed and will not vary with movements in the Davion’s share price.
The acquired technologies
WoundSkan is a smart wound dressing containing a temperature sensor and a passive NFC tag. It has no battery or internal power: scanning the dressing with a smartphone powers the sensor and sends the reading to the WoundSkan app. The app records each timestamped temperature reading alongside a reading history and patient notes, so clinicians can track wound temperature, a potential early sign of infection, without removing the dressing.
The Spektra Lateral Flow Test is a single-use screening platform. A onetime use base unit collects urine and saliva samples and takes one of ten colour-coded cartridges, each carrying antibodies for specific markers. Results are available in around two minutes and are sent to a smartphone by passive NFC.
The current cartridge range covers markers associated with certain cancers, hormonal imbalances, autoimmune conditions and neurodegenerative conditions. Although Spektra is not a diagnostic test, it is designed to identify anomalies that may warrant further clinical investigation.
Both technologies use the battery-free, smartphone-read approach that underpins Davion’s focus on health monitoring outside traditional clinical settings.
The acquisition includes the associated patents and patent applications, technical designs, software and algorithms, research and development data, testing information, regulatory documentation, prototypes and know-how. It also includes the rights to develop, manufacture, commercialise and license products incorporating the acquired intellectual property.
The transaction covers the intellectual property and associated assets only. Davion has not acquired Humaskan Ltd as a corporate entity, nor has it taken on its employees or assumed any of its liabilities.
Transaction terms
The consideration shares will be issued after a 90-day deferral period from listing, which will be on the 20th January 2027. For the following 90 days thereafter, each Seller may sell no more than 10% of Davion’s five-day average daily trading volume on any trading day. The cash consideration is payable by 19 February 2027, within 120 days of the start of trading of Davion’s shares on Nasdaq.
Strategy
The acquisition is Davion’s first since its direct listing on the Nasdaq Global Market on 22 October 2026. It follows the Group’s adoption of a direct commercialisation strategy in June 2026. Davion’s growth strategy combines the commercialisation of its proprietary technologies, including BreastCheck, with acquisitions across medical devices, healthcare services, medical distribution, healthcare technology and diagnostics.
To support its acquisition programme, Davion has established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond. The Group’s acquisition programme is overseen by its Operational Directorate, led by Chief Executive Officer Glenn Williams.
Glenn Williams, Chief Executive Officer of Davion Healthcare, commented:
“This acquisition is an important step in our plans to build a substantial international healthcare business, combining the development of our existing portfolio with the acquisition of complementary technologies.
“WoundSkan and Spektra are both innovative, practical technologies with considerable commercial potential. WoundSkan builds on our existing expertise in temperature-based monitoring, offering a way to assess wounds without removing dressings, while Spektra provides rapid screening for multiple conditions from a single sample. Both have applications across a range of healthcare settings.
“Following our recent Nasdaq listing, we are well positioned to accelerate the development and commercialisation of these technologies, while continuing to pursue further acquisition opportunities.”
Mark Komonoski Partner Integrous Communications Toll Free: 877-255-8483 Mobile: 403-470-8384
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.
The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.
The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday 22 October 2026 under ticker “DAVI”
Glenn Williams appointed Chief Executive Officer and Jeremy North Chief Operating Officer, effective on commencement of trading
New Operational Directorate established to lead commercialisation, operations, acquisitions and execution of the Group’s growth strategy
DUBLIN, Oct. 20, 2026 /PRNewswire/ — Davion Healthcare Plc (“Davion” or the “Company”), a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies, today announces that its ordinary shares are expected to commence trading on the Nasdaq Global Market on Thursday 22 October 2026, under the ticker symbol “DAVI” (Nasdaq: DAVI).
Davion designs, develops and commercialises non-invasive health monitoring technologies intended to make it easier for individuals to monitor their health outside traditional clinical environments. Its core Consumer Health portfolio comprises proprietary, home-based monitoring devices designed to support the early identification of potential medical anomalies.
The Company’s flagship product is BreastCheck, an FDA-registered, non-invasive at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. The test can be completed at home in less than 15 minutes, with results available through a mobile app or online. BreastCheck is intended to support proactive breast health monitoring and is not a replacement for mammography or clinical diagnosis.
The expected commencement of trading comes during Breast Cancer Awareness Month, as Davion advances the commercialisation and distribution of BreastCheck in the United States and internationally.
Alongside BreastCheck, Davion is developing a broader portfolio of proprietary health monitoring technologies. These include FootFlow, for monitoring indicators associated with circulation and diabetes-related blood flow issues; Testic, an at-home testicular health monitoring system; ThermaDerm, for the identification of skin anomalies; together with further technologies addressing wound monitoring, blood pressure and other areas of preventive healthcare.
Growth through commercialisation and acquisition
Davion’s growth strategy combines the commercialisation of its proprietary technologies with the acquisition of complementary healthcare businesses. Following the adoption of a direct commercialisation strategy in June 2026, the Group is developing its international manufacturing and distribution capabilities while pursuing acquisitions across medical devices, healthcare services, medical distribution, healthcare technology and diagnostics.
The Group is particularly focused on businesses capable of adding revenues, earnings, products, customers and established distribution capabilities.
To support this strategy, Davion recently established Davion Healthcare Finance Ltd and launched a £30 million five-year senior secured bond, providing dedicated financing to support its acquisition programme.
Executive Leadership
Glenn Williams will be appointed Chief Executive Officer and Jeremy North Chief Operating Officer, with both appointments taking effect upon commencement of trading on Nasdaq.
Mr Williams is a healthcare, finance and operations executive with more than 35 years’ experience across healthcare systems, pharmaceutical and medical device companies, insurance and private equity-backed businesses. He has led or participated in more than $1 billion of M&A and due-diligence activity and previously held senior roles at Care Finders Total Care, where he helped prepare the business for its subsequent sale in a transaction valued at more than $350 million.
Mr North has more than 30 years’ experience in corporate finance, M&A, fundraising, business transformation and public markets in the United States and United Kingdom. His previous roles include CEO and CFO of CloudMade Group, where he led the turnaround and subsequent sale of the business to Stellantis, together with prior Nasdaq board experience.
The current Chief Executive Officer, Jack Kaye, will become Chairman upon commencement of trading, continuing to provide strategic guidance to the Group and its Board. Sir Eric Peacock will step down as Chairman and will remain on the Board as a Non-Executive Director.
Operational Directorate
As part of the transition to Davion’s next stage of development, the Company is establishing an Operational Directorate as its principal executive management body, responsible for the day-to-day operation of the Group and execution of its strategy.
Led by Chief Executive Officer Glenn Williams, the Directorate will include the Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer, with other senior executives and advisers participating as required. Its responsibilities will include product commercialisation, international distribution, operational performance, acquisition evaluation and execution, and post-acquisition integration.
The Operational Directorate will report to the Board of Davion Healthcare Plc, which will retain responsibility for overall strategy, governance and oversight, including major financing and capital allocation decisions, material acquisitions, executive appointments and remuneration, risk management, audit, financial reporting and regulatory compliance.
The structure establishes a clear distinction between Board oversight and executive management, supporting the Group’s commercial and acquisition-led growth.
Advisors
Maxim Group LLC acted as financial advisor to the Company in connection with the Nasdaq listing.
Jack Kaye, current Chief Executive Officer and incoming Chairman of Davion Healthcare Plc, commented:
“The expected commencement of trading on Nasdaq is a major milestone for Davion and comes during Breast Cancer Awareness Month as we advance the commercialisation of our flagship BreastCheck technology.
“Alongside our broader portfolio of proprietary health monitoring technologies, we intend to pursue acquisitions that add revenues, earnings and commercial capabilities to the Group.
“The establishment of the Operational Directorate, led by Glenn and supported by Jeremy and the wider executive team, provides the management structure to deliver our growth plans. I look forward to working with them as we build Davion into a substantial international healthcare company.”
“Davion has developed a strong portfolio of proprietary healthcare technologies with significant commercial potential and has established a platform from which we can pursue both organic and acquisition-led growth.
“My focus will be on translating that potential into commercial performance: bringing products to market, expanding our distribution capabilities, strengthening the business operationally and identifying complementary acquisitions capable of accelerating the Group’s development.
“I am delighted to be joining Davion at such an important point in its development and look forward to working with Jack, Jeremy, the Board and the wider team.”
Jeremy North, incoming Chief Operating Officer, added:
“Davion has a clear opportunity to grow both organically and through acquisition. As Chief Operating Officer and a member of the Operational Directorate, my focus will be on execution: developing the Group’s operating capabilities, supporting the evaluation and completion of acquisition opportunities and ensuring that acquired businesses and technologies are integrated effectively.”
Mark Komonoski Partner Integrous Communications Toll Free: 877-255-8483 Mobile: 403-470-8384
About Davion Healthcare Plc
Davion Healthcare Plc is a next-generation digital healthcare company developing proprietary, non-invasive health monitoring technologies designed to support the early identification of medical anomalies outside traditional clinical environments.
The Company’s flagship product, BreastCheck, is an FDA-registered at-home breast health screening test designed to identify potential abnormalities through changes in breast temperature. Davion’s broader portfolio includes technologies addressing circulation and foot health, testicular health, skin anomalies, wound monitoring, blood pressure and other areas of preventive healthcare.
Davion’s growth strategy combines the development and commercialisation of its proprietary technologies with complementary acquisitions intended to expand the Group’s product portfolio and commercial, manufacturing and distribution capabilities.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as “believes,” “will,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions.
The statements in this release are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, the Company’s ability to license and protect its intellectual property, its ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against the Company, any governmental review of its products or practices, and other risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time, except as required by applicable law.
The investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.
View original content: